S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

NCT01809691 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1313

Enrollment

NETWORK

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: TAK-700
DRUG: Bicalutamide

Sponsor

SWOG Cancer Research Network

Collaborators

Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)